The company is riding high following FDA clearance for its tattoo removal medical device.
Sales are soaring at this marijuana stock, but rising revenue isn't the only thing you should know about its performance last quarter.
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Increasing demand for its forecasting software is sending sales soaring.
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
These biotech stocks could pop or drop next month following ASCO's annual conference.
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
Berkshire Hathaway is the single largest shareholder of these well-known companies.
Berkshire Hathaway sold these stocks last quarter, and that could mean you should sell them, too.
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
These were Berkshire Hathaway's biggest buys in the first quarter.
The price slipped on news of a share offering by one of its biggest investors.
Cannabis company Tilray's latest financial report includes plenty of pros and cons.
Canada's second-biggest marijuana stock by revenue is growing rapidly, but losses continue.
CannTrust's got big plans that could turn it into one of Canada's top pot stocks.
These cancer drug developers could report market-moving news soon.
Its been a tough few years for investors in this big-cap biotech, but signals are emerging that better days are ahead.
A new study is planned that could someday reshape colon cancer screenings.
Here's what you should know about this fast-growing cannabis company following its latest quarterly financial results.
Sales slipped from the fourth quarter, but there's still a lot to like about this company.